Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Deep anterior lamellar keratoplasty in children

Poster Details

First Author: N.Planas Domènech SPAIN

Co Author(s):    N. Barnils Garcia   E. Jurado Gonzalez                 

Abstract Details


To report our experience in deep anterior lamellar keratoplasty (DALK) in children


Hospital Sant Joan de Déu is a tertiary pediatric hospital located in Barcelona (Spain), which aims to provide integral care for children. It services patients of pediatric age from the surrounding Barcelona area and complex cases referred from the rest of Spain. The ophthalmology service is divided into subspecialities


Retrospective study of pediatric patients less than 18 years of age undergoing DALK from September 2012 to November 2014 was undertaken. DALK was attempted in 6 children (6 eyes). Main outcome measure: visual outcome and complications


Six eyes of six children (mean age 13.33 years) underwent DALK for keratoconus(2 cases), microbial keratitis (2), amiloidosis (1) and corneal scar (1). Big bubble was achieved in 2 eyes, while manual dissection was done in 4. No surgical complications. All the patients (follow-up between 2 months and 2 years) were evaluated for visual outcomes that varied from less 20/200 to 20/32 (mean cylinder -3.2 diopters). Complications were postoperative ocular hypertension (2) and opacity in peripheral interface between graft and receptor (1). All of them were treated with topical immunosuppresssion, only two received systemic immunosuppression. No cases of graft rejection


DALK is a feasible option in children with stromal corneal pathology. It is more technically challenging but offers advantages: less intraoperative complications and lower risk of graft rejection, even without the use of systemic immunosuppression

Financial Disclosure:


Back to Poster listing